- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dapagliflozin Enhances Metabolic Outcomes When Added to Insulin in T2DM, Suggests Study

A new study published in the Clinics journal revealed that the addition of dapagliflozin to insulin therapy may provide broader metabolic benefits, including better glycemic control, weight reduction, improved lipid profiles, and lower blood pressure. It was also associated with a favorable safety profile, supporting its potential role as an adjunct to insulin in selected patients with Type 2 Diabetes Mellitus (T2DM).
This 3-month study enrolled 86 patients with T2DM, who were randomly assigned to receive either insulin monotherapy or a combination of dapagliflozin and insulin. This research assessed key treatment outcomes, including glycemic control, lipid profile, body weight, body mass index (BMI), blood pressure, and treatment-related adverse events.
The combination therapy demonstrated superior performance across all major clinical endpoints. The most notable improvement was observed in glycated hemoglobin (HbA1c), the primary indicator of long-term blood glucose control. Patients receiving dapagliflozin with insulin achieved a 24.9% reduction in HbA1c, compared with 10.3% in those treated with insulin alone, highlighting the enhanced glucose-lowering efficacy of the combination regimen.
Fasting blood glucose declined by 23.6% compared with 5.6% in the insulin-only group, while two-hour postprandial blood glucose decreased by 25.1% versus 13.7%, respectively. Total cholesterol decreased by 35.1%, triglycerides by 15.9%, and low-density lipoprotein cholesterol (LDL-C) by 15.7%, while high-density lipoprotein cholesterol (HDL-C) increased by 16.3%. In comparison, the insulin-only group experienced more modest changes across these lipid parameters.
Patients receiving dapagliflozin also experienced greater reductions in body weight and BMI, with body weight declining by 5.4% and BMI by 9.8%, when compared to 3.3% and 4.3%, respectively, among those on insulin alone. Blood pressure also improved significantly, with systolic blood pressure reduced by 7.3% and diastolic blood pressure by 12.6%, outperforming insulin monotherapy.
The incidence of adverse events was 71.4% lower in the dapagliflozin-plus-insulin group, which represented a statistically significant improvement. Also, no cases of diabetic ketoacidosis were reported during the trial. Overall, the findings suggest that dapagliflozin as an adjunct to insulin delivers broad metabolic benefits beyond blood glucose control, including improvements in lipid profile, body weight, and blood pressure, while maintaining a favorable safety profile.
Reference:
Sun, L., Liu, G., Liang, B., & You, H. (2026). Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial. Clinics (Sao Paulo, Brazil), 81(101116), 101116. https://doi.org/10.1016/j.clinsp.2026.101116
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

